NIMENRIX (Pfizer Australia Pty Ltd)
Product name
NIMENRIX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
200 working days (255)
Active ingredients
Meningococcal polysaccharide group W135; Meningococcal polysaccharide group C; Meningococcal polysaccharide Group Y; Tetanus toxoid; Meningococcal polysaccharide group A
Registration type
EOI
Indication
NIMENRIX (injection) is now indicated for active immunisation of individuals from 6 weeks of age against invasive meningococcal diseases caused by Neisseria meningitidis groups A, C, W-135 and Y.